|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 49.25 USD | -4.41% |
|
-7.75% | -6.08% |
| 10-16 | Crispr Therapeutics Insider Sold Shares Worth $720,373, According to a Recent SEC Filing | MT |
| 10-15 | UBS Initiates CRISPR Therapeutics at Neutral With $52 Price Target | MT |
| Market Cap | 4.76B 4.24B 3.92B 3.57B 6.73B 452B 6.84B 47.13B 18.58B 236B 17.87B 17.49B 751B | P/E 2026 * |
-11.3x | P/E 2027 * | -14.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3.23B 2.88B 2.66B 2.42B 4.56B 307B 4.64B 31.98B 12.61B 160B 12.13B 11.87B 510B | EV / Sales 2026 * |
79.9x | EV / Sales 2027 * | 23.7x |
| Free-Float |
94.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CRSP | Delayed | |
CBOE
| CRSP | Real-time | |
|
Tradegate
| 1CG | Real-time | |
|
Mexican S.E.
| CRSP N | End-of-day quote | |
|
Boerse Muenchen
| 1CG | Real-time | |
|
London S.E.
| 0VRQ | Delayed | |
|
Börse Stuttgart
| 1CG | Delayed | |
|
Berne S.E.
| 1CG | End-of-day quote | |
|
Deutsche Boerse AG
| 1CG | Delayed |
Last Transcript: CRISPR Therapeutics AG
| 1 day | -4.41% | ||
| 1 week | -7.75% | ||
| Current month | -10.97% | ||
| 1 month | -14.09% | ||
| 3 months | +3.08% | ||
| 6 months | -15.07% | ||
| Current year | -6.08% |
| 1 week | 48.91 |  | 53.21 |
| 1 month | 48.91 | | 60.72 |
| Current year | 44.12 | | 63.45 |
| 1 year | 44.12 | | 75.06 |
| 3 years | 30.04 | | 91.1 |
| 5 years | 30.04 | | 102.96 |
| 10 years | 11.63 | | 220.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 47 | 2017-11-30 |
Raju Prasad
DFI | Director of Finance/CFO | 42 | 2023-03-13 |
Naimish Patel
CTO | Chief Tech/Sci/R&D Officer | - | 2024-05-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Simeon George
BRD | Director/Board Member | 49 | 2015-04-28 |
Ali Behbahani
BRD | Director/Board Member | 49 | 2015-03-31 |
Samarth Kulkarni
CHM | Chairman | 47 | 2023-09-14 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/14/26 | Sell | General Counsel | -1,040 | 0.0011% | ||
| 10/14/26 | Sell | Chief Executive Officer | -4,098 | 0.0042% | ||
| 10/6/26 | Exercice | General Counsel | 5,970 | 0.0062% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.41% | -7.75% | -28.78% | +12.80% | 4.76B | |
| -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -1.07% | +2.33% | +19.43% | +9.98% | 22.5B | |
| Average | -1.94% | -1.09% | +38.09% | +86.17% | 37.71B | |
| Weighted average by Cap. | -2.22% | -0.59% | +43.32% | +95.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 40.44M 36.02M 33.31M 30.33M 57.11M 3.84B 58.06M 400M 158M 2B 152M 149M 6.38B | 151M 135M 125M 113M 214M 14.36B 217M 1.5B 590M 7.49B 567M 555M 23.86B |
| Net income | -432M -385M -356M -324M -611M -41.05B -621M -4.28B -1.69B -21.41B -1.62B -1.59B -68.23B | -342M -305M -282M -256M -483M -32.47B -491M -3.38B -1.33B -16.93B -1.28B -1.26B -53.96B |
| Net Debt | -1.53B -1.36B -1.26B -1.15B -2.16B -145B -2.2B -15.15B -5.97B -75.8B -5.74B -5.62B -242B | -1.17B -1.04B -965M -879M -1.65B -111B -1.68B -11.59B -4.57B -58.01B -4.4B -4.3B -185B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | US$49.25 | -4.41% | 1,524,985 |
| 26-10-15 | US$51.52 | +2.59% | 1,352,945 |
| 26-10-14 | US$50.22 | +0.24% | 1,707,556 |
| 26-10-13 | US$50.10 | -2.81% | 1,342,658 |
| 26-10-12 | US$51.55 | -3.45% | 1,106,306 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRSP Stock
Select your edition
All financial news and data tailored to specific country editions
